Antibody cocktail effective against variants of SARS-CoV-2

Abstract Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutral...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kang-Hao Liang, Pao-Yin Chiang, Shih-Han Ko, Yu-Chi Chou, Ruei-Min Lu, Hsiu-Ting Lin, Wan-Yu Chen, Yi-Ling Lin, Mi-Hua Tao, Jia-Tsrong Jan, Han-Chung Wu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Receptor-binding domain (RBD) Neutralizing antibody Cocktail therapy Medicine R
Acceso en línea:	https://doaj.org/article/7e765143995640ccb0b25900e804ab12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e765143995640ccb0b25900e804ab12
record_format	dspace
spelling	oai:doaj.org-article:7e765143995640ccb0b25900e804ab122021-11-28T12:14:17ZAntibody cocktail effective against variants of SARS-CoV-210.1186/s12929-021-00777-91423-0127https://doaj.org/article/7e765143995640ccb0b25900e804ab122021-11-01T00:00:00Zhttps://doi.org/10.1186/s12929-021-00777-9https://doaj.org/toc/1423-0127Abstract Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing antibodies. Methods We analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluate efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments. Results The tested RBD-chAbs, except RBD-chAb-25, maintained binding ability to spike proteins from SARS-CoV-2 variants. However, only RBD-chAb-45 and -51 retained neutralizing activities; RBD-chAb-1, -15, -25 and -28 exhibited diminished neutralization for all SARS-CoV-2 variants. Notably, several cocktails of our antibodies showed low IC50 values (3.35–27.06 ng/ml) against the SARS-CoV-2 variant pseudoviruses including United Kingdom variant B.1.1.7 (Alpha), South Africa variant B.1.351 (Beta), Brazil variant P1 (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), and India variants, B.1.617.1 (Kappa) and B.1.617.2 (Delta). RBD-chAb-45, and -51 showed PRNT50 values 4.93–37.54 ng/ml when used as single treatments or in combination with RBD-chAb-15 or -28, according to plaque assays with authentic Alpha, Gamma and Delta SARS-CoV-2 variants. Furthermore, the antibody cocktail of RBD-chAb-15 and -45 exhibited potent prophylactic and therapeutic effects in Delta SARS-CoV-2 variant-infected hamsters. Conclusions The cocktail of RBD-chAbs exhibited potent neutralizing activities against SARS-CoV-2 variants. These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta.Kang-Hao LiangPao-Yin ChiangShih-Han KoYu-Chi ChouRuei-Min LuHsiu-Ting LinWan-Yu ChenYi-Ling LinMi-Hua TaoJia-Tsrong JanHan-Chung WuBMCarticleSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Receptor-binding domain (RBD)Neutralizing antibodyCocktail therapyMedicineRENJournal of Biomedical Science, Vol 28, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Receptor-binding domain (RBD) Neutralizing antibody Cocktail therapy Medicine R
spellingShingle	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Receptor-binding domain (RBD) Neutralizing antibody Cocktail therapy Medicine R Kang-Hao Liang Pao-Yin Chiang Shih-Han Ko Yu-Chi Chou Ruei-Min Lu Hsiu-Ting Lin Wan-Yu Chen Yi-Ling Lin Mi-Hua Tao Jia-Tsrong Jan Han-Chung Wu Antibody cocktail effective against variants of SARS-CoV-2
description	Abstract Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing antibodies. Methods We analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluate efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments. Results The tested RBD-chAbs, except RBD-chAb-25, maintained binding ability to spike proteins from SARS-CoV-2 variants. However, only RBD-chAb-45 and -51 retained neutralizing activities; RBD-chAb-1, -15, -25 and -28 exhibited diminished neutralization for all SARS-CoV-2 variants. Notably, several cocktails of our antibodies showed low IC50 values (3.35–27.06 ng/ml) against the SARS-CoV-2 variant pseudoviruses including United Kingdom variant B.1.1.7 (Alpha), South Africa variant B.1.351 (Beta), Brazil variant P1 (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), and India variants, B.1.617.1 (Kappa) and B.1.617.2 (Delta). RBD-chAb-45, and -51 showed PRNT50 values 4.93–37.54 ng/ml when used as single treatments or in combination with RBD-chAb-15 or -28, according to plaque assays with authentic Alpha, Gamma and Delta SARS-CoV-2 variants. Furthermore, the antibody cocktail of RBD-chAb-15 and -45 exhibited potent prophylactic and therapeutic effects in Delta SARS-CoV-2 variant-infected hamsters. Conclusions The cocktail of RBD-chAbs exhibited potent neutralizing activities against SARS-CoV-2 variants. These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta.
format	article
author	Kang-Hao Liang Pao-Yin Chiang Shih-Han Ko Yu-Chi Chou Ruei-Min Lu Hsiu-Ting Lin Wan-Yu Chen Yi-Ling Lin Mi-Hua Tao Jia-Tsrong Jan Han-Chung Wu
author_facet	Kang-Hao Liang Pao-Yin Chiang Shih-Han Ko Yu-Chi Chou Ruei-Min Lu Hsiu-Ting Lin Wan-Yu Chen Yi-Ling Lin Mi-Hua Tao Jia-Tsrong Jan Han-Chung Wu
author_sort	Kang-Hao Liang
title	Antibody cocktail effective against variants of SARS-CoV-2
title_short	Antibody cocktail effective against variants of SARS-CoV-2
title_full	Antibody cocktail effective against variants of SARS-CoV-2
title_fullStr	Antibody cocktail effective against variants of SARS-CoV-2
title_full_unstemmed	Antibody cocktail effective against variants of SARS-CoV-2
title_sort	antibody cocktail effective against variants of sars-cov-2
publisher	BMC
publishDate	2021
url	https://doaj.org/article/7e765143995640ccb0b25900e804ab12
work_keys_str_mv	AT kanghaoliang antibodycocktaileffectiveagainstvariantsofsarscov2 AT paoyinchiang antibodycocktaileffectiveagainstvariantsofsarscov2 AT shihhanko antibodycocktaileffectiveagainstvariantsofsarscov2 AT yuchichou antibodycocktaileffectiveagainstvariantsofsarscov2 AT rueiminlu antibodycocktaileffectiveagainstvariantsofsarscov2 AT hsiutinglin antibodycocktaileffectiveagainstvariantsofsarscov2 AT wanyuchen antibodycocktaileffectiveagainstvariantsofsarscov2 AT yilinglin antibodycocktaileffectiveagainstvariantsofsarscov2 AT mihuatao antibodycocktaileffectiveagainstvariantsofsarscov2 AT jiatsrongjan antibodycocktaileffectiveagainstvariantsofsarscov2 AT hanchungwu antibodycocktaileffectiveagainstvariantsofsarscov2
_version_	1718408148733132800

Antibody cocktail effective against variants of SARS-CoV-2

Ejemplares similares